報價延遲最少15分鐘:2024/11/16 09:01 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
135.05 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-19.16/4.56
|
|
企業價值
24.83B
|
| 資產負債 |
|
每股賬面淨值
9.01
|
| 現金流量 |
|
現金流量率
0.02
|
| 損益表 |
|
收益
4.58B
|
|
每股收益
28.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/11/16 09:01 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications. |